FOXO4-DRI Limited Evidence

What It Is

FOXO4-DRI ("FOXO4 D-Retro-Inverso") is a synthetic peptide engineered to disrupt the protein–protein interaction between forkhead box O transcription factor 4 (FOXO4) and tumor suppressor p53 (TP53) inside senescent cells. It was first described in a March 2017 paper in Cell by Marjolein Baar, Peter de Keizer, and colleagues at Erasmus University Medical Center, Netherlands, working in collaboration with Judith Campisi's lab at the Buck Institute for Research on Aging (Baar MP et al., Cell. 2017;169(1):132-147.e16; PMID 28340339).

Structurally, FOXO4-DRI is a short peptide (the published sequence is ~15 amino acids in the original Baar paper; commercial-vendor formulations and follow-up structural papers reference variants of 15–29 amino acids depending on which publication's sequence is replicated) derived from the p53-binding region of human FOXO4. Two unusual structural modifications distinguish it from a conventional research peptide:

• D-amino acids — All amino acids are the D-stereoisomer (mirror-image of the L-amino acids that compose endogenous proteins). Mammalian proteases cleave L-amino-acid peptides but recognize D-amino acid backbones poorly, dramatically extending intracellular half-life from minutes (typical for short L-peptides) to hours.
• Retro-inverso sequence — The amino-acid sequence is reversed, with corresponding inversion of peptide bond directionality. The retro-inverso strategy preserves the side-chain spatial arrangement of the parent L-peptide while eliminating proteolytic susceptibility.

The combined "DRI" (D-retro-inverso) design is a well-established medicinal-chemistry approach for converting a short L-peptide hit into a protease-resistant tool compound while preserving the binding pharmacophore. It is not a delivery technology and does not by itself improve cell penetration; the FOXO4-DRI peptide is reported to be cell-permeable based on the polybasic / cationic amphipathic character of its N-terminal residues.

FOXO4-DRI is supplied exclusively as a research-grade synthetic peptide. There is no FDA-approved or any-jurisdiction-approved therapeutic version, no investigational therapeutic program with an active IND, and no compounding-pharmacy availability. The only legitimate sources are research-reagent vendors (NovoPro, Peptide Sciences, custom academic synthesis houses) selling material strictly for laboratory use.

Mechanism of Action

FOXO4-DRI's mechanism is a precise, single-target intervention on a specific protein–protein interaction. Unlike most "research peptides" with broad pleiotropic activity, FOXO4-DRI was rationally designed to do exactly one thing:

• Senescent cells upregulate FOXO4 — In response to DNA damage, oncogenic stress, or replicative exhaustion, cells can enter a senescent state — proliferation arrest plus a senescence-associated secretory phenotype (SASP) that releases pro-inflammatory cytokines, matrix metalloproteinases, and growth factors into surrounding tissue. Senescent cells upregulate FOXO4 as part of their survival apparatus. FOXO4 is a member of the FOXO transcription factor family alongside FOXO1, FOXO3, and FOXO6, and is normally expressed only at low levels in most adult tissues.
• FOXO4 sequesters p53 in nuclear bodies — In senescent cells, FOXO4 binds the disordered N-terminal transactivation domain of p53, locking p53 into nuclear PML-body sequestration. This prevents p53 from doing its normal apoptosis-driving job: it cannot transcriptionally activate pro-apoptotic genes (Bax, Puma, Noxa) and cannot translocate to mitochondria where it can directly trigger transcription-independent apoptosis via interaction with Bcl-2 family proteins (Mihara et al., 2003 mechanism).
• FOXO4-DRI competitively displaces p53 from FOXO4 — The peptide binds FOXO4's p53-interaction surface, competitively displacing endogenous p53. Released p53 phosphorylated at Ser15 (active form) is excluded from the nucleus and translocates to mitochondria, where it engages Bax/Bak and triggers cytochrome-c-dependent caspase activation and apoptosis (Bourgeois & Madl, FEBS Lett 2018).
• Senescent-cell selectivity — Because FOXO4 is upregulated specifically in senescent cells, the peptide preferentially affects senescent cells. In healthy cells with low FOXO4 expression, the same peptide produces minimal effect. The published in-vitro selectivity is approximately 10× higher viability impact on senescent vs non-senescent IMR90 fibroblasts (Baar 2017; Bourgeois 2018). Meaningful but not absolute — perhaps 1 healthy cell is affected for every 10 senescent cells eliminated at therapeutically relevant concentrations.
• Structural insights — 2025 Nature Communications — Recent NMR and structural-biology work (Nat Commun 2025; doi 10.1038/s41467-025-60844-9) confirmed that FOXO4-DRI binds the disordered N-terminal transactivation domain of p53 with a binding mode similar to native FOXO4. The peptide-p53 interaction involves the same hydrophobic pocket that other transcriptional cofactors use to engage p53's transactivation domain, providing structural rationale for the competitive disruption mechanism.
• Pathway engagement — Downstream of disrupted FOXO4-p53 binding, the senescent cell undergoes intrinsic apoptosis: mitochondrial outer-membrane permeabilization → cytochrome-c release → caspase-9 activation → executioner caspase (3/7) activation → DNA fragmentation and apoptotic cell death. SA-β-gal-positive cell counts decline within hours of effective dosing in cell culture; in vivo effects on senescent-cell burden are reported 2–7 days post-dosing.
• Selectivity for FOXO4 over FOXO1/FOXO3 — The peptide sequence corresponds to a region of FOXO4 that differs from FOXO1 and FOXO3 in primary amino-acid composition, giving the DRI peptide preferential affinity for FOXO4 over its FOXO siblings. This isoform selectivity is important because FOXO1 and FOXO3 have substantially broader physiological functions in healthy cells and broad pan-FOXO inhibition would be far less safe.

What the Research Shows

FOXO4-DRI's published evidence base is unusually concentrated. The vast majority of citations trace back to one landmark 2017 Cell paper plus a small set of follow-up studies — fewer than 30 PubMed-indexed papers as of April 2026. The published evidence falls into four buckets:

• The Baar 2017 landmark paper — Baar MP, Brandt RMC, Putavet DA, Klein JDD, et al. Cell. 2017 Mar 23;169(1):132-147.e16. PMID 28340339. The defining publication. Demonstrated: (a) FOXO4-DRI selectively kills senescent IMR90 fibroblasts in vitro with ~10-fold selectivity; (b) p53 nuclear exclusion and mitochondrial translocation as the apoptotic mechanism; (c) in-vivo administration to fast-aged XpdTTD/TTD mice (DNA-repair-deficient progeroid model) and naturally aged 24-month-old mice restored fitness, fur density, and renal function; (d) FOXO4-DRI neutralized doxorubicin chemotherapy-induced premature senescence in mouse cancer models. The paper was accompanied by a commentary in the same Cell issue (PMID 28340347) framing it as a proof-of-concept for "rejuvenation by therapeutic elimination of senescent cells."
• Mechanistic and structural follow-up — Bourgeois & Madl, FEBS Letters 2018 (DOI 10.1002/1873-3468.13057). The first dedicated mechanistic review establishing the FOXO4-p53 axis as a regulated cellular senescence checkpoint and characterizing FOXO4-DRI's specificity vs FOXO1 and FOXO3. Nature Communications 2025 structural work confirmed the disordered p53 transactivation domain as the binding target.
• In-vitro confirmatory studies — He L et al. PMC8116695 (2021) — chondrocyte senescence model showing FOXO4-DRI removes >50% of PDL9 senescent chondrocytes with reduction in SA-β-gal staining and altered SOX9, MMP12, MMP13 expression. Yu Y et al. Communications Biology 2025 (s42003-025-07738-0) — keloid fibroblast model showing FOXO4-DRI selectively eliminates senescent keloid fibroblasts via p53-pS15 nuclear exclusion. These independent confirmatory studies replicate the senolytic mechanism in disease-relevant cell systems.
• Aged Leydig cell mouse study — Zhang C, Xie Y, Chen H, Lv L, et al. Aging (Albany NY). 2020;12(2):1272-1284. PMID 31959736. FOXO4-DRI administered to aged mice reduced p53, p21, and p16 in testes and partially restored testosterone secretion via senescent-Leydig-cell elimination. One of the few published in-vivo aging-tissue studies replicating the original Baar findings in a different organ system.
• Computational / next-generation peptide design — Le HH, Cinaroglu SS, Manalo EC, et al. EBioMedicine. 2021;73:103646. PMC8601985. Computational modeling of the FOXO4-TP53 interface led to design of "ES2" peptides reportedly 3–7× more potent than FOXO4-DRI in vitro and in vivo. This work positions FOXO4-DRI as a first-generation tool already improved upon in the academic pipeline.
• No completed human clinical trials — As of April 2026, no FOXO4-DRI clinical trial is registered on ClinicalTrials.gov, no IND application is publicly disclosed, and no Phase 1 safety study has been published. The only "human-relevant" data is in-vitro work on human cell lines.

Human Data

There is no published human clinical trial data on FOXO4-DRI for any indication. As of April 2026:

• No registered clinical trial — A search of ClinicalTrials.gov and EudraCT returns no FOXO4-DRI protocols, completed or in progress.
• No Phase 1 safety data — No first-in-human safety/PK study has been published.
• No IND filing publicly disclosed — Although Cleara Biotech (the Erasmus-University spinout founded by de Keizer to commercialize FOXO4-DRI and successor compounds) has stated intent to advance senolytic peptides to human studies, no public IND filing or Phase 1 launch has occurred.
• No human pharmacokinetic data — All published PK is from rodent IP / SubQ administration. Plasma half-life, distribution to senescent-cell-rich tissues, and metabolic clearance pathways in humans are unknown.
• Anecdotal community use — A small number of self-experimenters in the longevity community have reported FOXO4-DRI use (typically ~5 mg/kg SubQ for 3 doses) on podcasts and forums. These reports are not clinical data — they are uncontrolled, unblinded, often single-individual, and rarely include before/after biomarker characterization. They do not constitute evidence of safety or efficacy.
• In-vitro human cell data — Multiple papers have shown FOXO4-DRI senolytic activity in human cell lines (IMR90 fibroblasts, A375 melanoma, in-vitro-expanded chondrocytes, keloid fibroblasts). This is the closest available "human" data — it confirms the mechanism operates on human cells in culture but cannot establish in-vivo safety, pharmacokinetics, dose, or efficacy.

Dosing from the Literature

All published FOXO4-DRI dosing is from rodent studies. Community protocols extrapolate from these by allometric scaling — an approach with substantial uncertainty for a peptide with no completed human PK study.

Reconstitution & Storage

FOXO4-DRI is supplied as a synthetic lyophilized peptide by research-reagent and longevity-community vendors:

• Solubility — Sparingly soluble in water; soluble in DMSO. Working stocks are typically prepared in DMSO at 25 mM and diluted into aqueous buffers for assay use.
• Stability advantage of D-retro-inverso form — The D-amino acid composition resists protease cleavage, so reconstituted FOXO4-DRI is far more stable than equivalent L-peptides. Lyophilized stable for years at −20°C; reconstituted aliquots stable for months at −80°C with avoidance of repeated freeze-thaw.
• Inspection — Should be a white-to-off-white lyophilized powder; reconstituted solution clear and colorless. Discard if discolored or showing visible particulate.
• Sterility — Synthetic peptides for research use are generally not supplied sterile by default; sterile filtration through 0.22 μm filter is required prior to any in-vivo administration.

→ Use the Kalios Dosing Calculator for vial conversions

Side Effects & Risks

FOXO4-DRI's safety profile is essentially uncharacterized in humans. Known and theoretical risks:

• Cancer risk (theoretical, important) — p53 is the most-mutated tumor suppressor in human cancer. Manipulating p53-pathway activity in patients with undiagnosed pre-cancerous lesions or low-grade incidental tumors carries unquantified risk. The senolytic mechanism is intended to be cell-selective for senescent cells, but the 10:1 in-vitro selectivity does mean some impact on healthy and possibly transformed cells. Active or recent cancer is a clear contraindication.
• Removal of beneficial senescent cells — Some senescent cells serve protective functions: wound healing (myofibroblast senescence prevents fibrosis), hepatic regeneration, embryonic patterning, suppression of latent micro-cancers. Indiscriminate senolytic use during these processes could be counterproductive. Active wound healing, post-surgery recovery, heavy training-induced microtrauma, and active tissue repair are conceptual contraindications.
• p53 pathway perturbation — Long-term consequences of repeated FOXO4-p53 disruption in healthy adults are unknown. Single-cycle administration in mouse studies appears tolerated; chronic repeated dosing has not been characterized in long-term whole-animal studies in healthy older mammals.
• Acute toxicity — Reported as well-tolerated in mice at 5 mg/kg IP every other day × 3. No published acute toxicity data in any other species.
• Pulmonary considerations — Some senolytic agents have been associated with pulmonary effects in patients with pre-existing pulmonary disease. FOXO4-DRI lung effects have not been specifically characterized; pre-existing significant pulmonary disease is a conceptual contraindication.
• Pregnancy and lactation — No data; absolute contraindication by analogy with other p53-modulating compounds.
• Pediatric — Not studied; contraindicated in anyone under 18.
• Drug interactions — Largely unstudied. Co-administration with cytotoxic chemotherapy is mechanistically interesting (the original Baar paper showed FOXO4-DRI neutralizes doxorubicin chemotoxicity) but should occur only in a clinical trial setting.
• Immune modulation — Senescent immune cell elimination could plausibly alter immune function in either direction; immunosuppressed patients should not use FOXO4-DRI.
• Lipopolysaccharide / endotoxin — Synthetic peptide preparations from low-tier vendors may carry endotoxin contamination; in-vivo administration of endotoxin-contaminated material can produce acute systemic inflammatory reactions independent of the peptide pharmacology.
• Sourcing / purity — As a research-only synthetic peptide, FOXO4-DRI quality varies dramatically between vendors. Independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation of D-amino acid retro-inverso sequence, endotoxin testing for in-vivo applications) is the practical floor for due diligence.

Bloodwork & Monitoring

No clinical monitoring protocol has been established for FOXO4-DRI in humans. For research-context awareness:

• Cancer screening (essential) — Age-appropriate cancer screening completed and current before any FOXO4-DRI exposure: colonoscopy, mammography, PSA, low-dose chest CT for high-risk smokers, dermatologic screening. Active or recent malignancy is a clear contraindication.
• Baseline CMP and CBC — Standard pre-treatment chemistry; document baseline organ function before any senolytic exposure.
• Inflammatory markers — hs-CRP, IL-6 baseline. Theoretically, effective senolysis should reduce SASP-driven inflammation; this could be tracked over months.
• Senescence-associated biomarkers — In a research setting, senescence-associated β-galactosidase activity in PBMCs, p16^INK4a expression, and SASP cytokine panels (IL-6, IL-8, MCP-1, MMP-1, MMP-3) provide objective tracking of senescent cell burden change.
• Renal function — Per the original Baar mouse data showing renal function restoration; eGFR and urinary albumin baseline and post-cycle for research-tracking purposes.
• Hormonal panels (men) — Per the Zhang 2020 Leydig cell data, total and free testosterone before and after a cycle is a research-relevant biomarker.

Commonly Stacked With

FOXO4-DRI has no established human stacking literature. In academic research and community-extrapolation contexts, conceptually relevant pairings include:

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching FOXO4-DRI often also look at these:

Next Steps

Key References

1. Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID: 28340339. (The defining FOXO4-DRI paper.)
2. Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, van Deursen JM. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell. 2017;169(1):3-5. PMID: 28340347. (Editorial commentary in same Cell issue framing the Baar 2017 paper as a senolytic field milestone.)
3. Bourgeois B, Madl T. Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett. 2018;592(12):2083-2097. DOI: 10.1002/1873-3468.13057. (The first dedicated mechanistic review establishing the FOXO4-p53 axis as a senescent cell survival checkpoint.)
4. Zhang C, Xie Y, Chen H, Lv L, Yao J, Zhang M, Xia K, Feng X, Li Y, Liang X, Sun X, Deng C, Liu G. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PMID: 31959736.
5. Le HH, Cinaroglu SS, Manalo EC, Ors A, Gomes MM, Duan Sahbaz B, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine. 2021;73:103646. PMC: PMC8601985. (Computational design of "ES2" peptides 3–7× more potent than FOXO4-DRI.)
6. Le H, Cinaroglu SS, Manalo EC, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576. PMC: PMC8116695.
7. Yu Y, Zhang R, Li Y, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025. DOI: 10.1038/s42003-025-07738-0. (Independent confirmation of senolytic mechanism in keloid fibroblast model.)
8. Stryeck S, Baar MP, Brandt RMC, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16. DOI: 10.1038/s41467-025-60844-9. (NMR / structural-biology characterization of the FOXO4-DRI binding mode on p53.)
9. Zhao Y, Tyshkovskiy A, Muñoz-Espín D, et al. Naked mole rats can undergo developmental, oncogene-induced and DNA damage-induced cellular senescence. Proc Natl Acad Sci U S A. 2018;115(8):1801-1806. (Comparative senescence-biology context.)
10. Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. PMID: 29988130. (The Mayo Clinic D+Q senolytics paper — comparator framework.)
11. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536. PMID: 32686219. (Senolytics field overview placing FOXO4-DRI in context.)
12. Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. PMID: 31542391. (The first published human senolytic clinical trial — comparator context for the absence of any FOXO4-DRI human trial.)
13. Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. PMID: 30616998. (D+Q pilot in IPF — comparator framework.)
14. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11(3):577-590. PMID: 12667443. (Mechanistic foundation for the mitochondrial p53 apoptotic pathway that FOXO4-DRI engages.)
15. de Keizer PL, Burgering BM, Dansen TB. Forkhead box o as a sensor, mediator, and regulator of redox signaling. Antioxid Redox Signal. 2011;14(6):1093-1105. PMID: 20945997. (Pre-FOXO4-DRI mechanistic background on FOXO4 as a stress sensor.)
16. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14(2):83-97. PMID: 23325358. (Comprehensive FOXO transcription factor family review.)
17. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424-1435. PMID: 26646499. (Cellular senescence field background.)
18. Freund A, Patil CK, Campisi J. p53 and the senescence-associated secretory phenotype. Aging Cell. 2011;10(4):636-647. (Foundational p53-SASP relationship paper.)
19. Cleara Biotech corporate disclosures. Erasmus University Medical Center spinout pursuing senolytic peptide development. (Public-domain corporate context for the FOXO4-DRI commercial pipeline.)
20. ClinicalTrials.gov / EudraCT. Search results for "FOXO4-DRI" — no registered trials as of April 2026. (Documentation of the absence of any registered human clinical trial.)